Bachem Holding (BANB) Resumen de Acciones
Bachem Holding AG, junto con sus filiales, suministra productos para investigación, desarrollo clínico y aplicación comercial a empresas farmacéuticas y biotecnológicas de todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 3/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en BANB a partir de nuestros controles de riesgos.
BANB Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 249.99
FV
71.5% infravalorado descuento intrínseco62.01%
Revenue growth p.a.
167
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Competidores de Bachem Holding AG
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CHF 71.15 |
| Máximo en las últimas 52 semanas | CHF 83.25 |
| Mínimo de 52 semanas | CHF 48.52 |
| Beta | 0.81 |
| Cambio en 1 mes | 4.71% |
| Variación en 3 meses | 2.45% |
| Cambio de 1 año | 22.67% |
| Variación en 3 años | -4.43% |
| Variación en 5 años | -38.98% |
| Variación desde la OPV | 408.21% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 15
BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside
Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.Artículo de análisis • Jul 04
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
Actualización de narrativa • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Recent updates
Actualización de narrativa • Jul 15
BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside
Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.Artículo de análisis • Jul 04
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.Actualización de narrativa • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Actualización de narrativa • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
Actualización de narrativa • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Nueva narrativa • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Actualización de narrativa • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Actualización de narrativa • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.Actualización de narrativa • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.Actualización de narrativa • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.Actualización de narrativa • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.Actualización de narrativa • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.Actualización de narrativa • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.Actualización de narrativa • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.Actualización de narrativa • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.Artículo de análisis • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...Artículo de análisis • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...Actualización de narrativa • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Artículo de análisis • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...Artículo de análisis • Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
The market for Bachem Holding AG's ( VTX:BANB ) stock was strong after it released a healthy earnings report last week...Artículo de análisis • Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Bachem Holding AG ( VTX:BANB ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Nueva narrativa • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Rentabilidad de los accionistas
| BANB | CH Life Sciences | Mercado CH | |
|---|---|---|---|
| 7D | -4.4% | -3.5% | 0.4% |
| 1Y | 22.7% | 2.4% | 16.1% |
Rentabilidad vs. Industria: BANB superó a la industria Swiss Life Sciences, que obtuvo un rendimiento del 1.2% el año pasado.
Rentabilidad vs. Mercado: BANB superó al mercado Swiss, que obtuvo un rendimiento del 15.8% el año pasado.
Volatilidad de los precios
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 5.4% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.2% |
Precio estable de las acciones: BANB no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Swiss.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BANB (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, junto con sus filiales, suministra productos para investigación, desarrollo clínico y aplicación comercial a empresas farmacéuticas y biotecnológicas de todo el mundo. Se dedica al desarrollo, producción y apoyo normativo de ingredientes farmacéuticos activos peptídicos, como nuevas entidades químicas (NCE) peptídicas y oligonucleotídicas. La empresa también ofrece NCE comerciales y genéricos; y servicios de gestión de proyectos, calidad y regulación, analítica, producción de buenas prácticas de fabricación, producción de grado de investigación y suministro e integración vertical.
Resumen de fundamentos de Bachem Holding AG
| Estadísticas fundamentales de BANB | |
|---|---|
| Capitalización bursátil | CHF 5.33b |
| Beneficios(TTM) | CHF 148.79m |
| Ingresos (TTM) | CHF 695.07m |
35.8x
Ratio precio-beneficio (PE)7.7x
Ratio precio-ventas (PS)¿Está BANB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BANB | |
|---|---|
| Ingresos | CHF 695.07m |
| Coste de los ingresos | CHF 495.34m |
| Beneficio bruto | CHF 199.73m |
| Otros gastos | CHF 50.94m |
| Beneficios | CHF 148.79m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
Jul 30, 2026
| Beneficios por acción (BPA) | 1.99 |
| Margen bruto | 28.74% |
| Margen de beneficio neto | 21.41% |
| Ratio deuda/patrimonio | 3.9% |
¿Cómo se ha desempeñado BANB a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.3%
Rentabilidad actual por dividendo45%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/20 04:03 |
| Precio de las acciones al final del día | 2026/07/17 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bachem Holding AG está cubierta por 17 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |